Campylobacter jejuni

Last updated

Campylobacter jejuni
ARS Campylobacter jejuni.jpg
Scientific classification OOjs UI icon edit-ltr.svg
Domain: Bacteria
Kingdom: Pseudomonadati
Phylum: Campylobacterota
Class: "Campylobacteria"
Order: Campylobacterales
Family: Campylobacteraceae
Genus: Campylobacter
Species:
C. jejuni
Binomial name
Campylobacter jejuni
(Jones and Little, 1931) Veron & Chatelain, 1973

Campylobacter jejuni is a Gram-negative, helical-shaped, motile, microaerophilic, pathogenic bacterium in the genus Campylobacter. It is commonly found in the intestinal tracts of poultry and other animals and is a major cause of bacterial gastroenteritis in humans worldwide. Infections, known as campylobacteriosis, is most often acquired through consumption of contaminated or undercooked poultry, unpasteurized milk, or contaminated water.

Contents

C. jejuni has several characteristics that contribute to its ability to survive and colonize its hosts. Its flagella allow it to move though intestinal mucus and interact with host cells, while various virulence factors contribute to adherence, invasion, and disease development. The bacterium also possesses metabolic and genetic feature that support its survival under different environmental and host conditions.

In humans, C. jejuni infections primarily causes intestinal inflammation and symptoms such as diarrhea, abdominal pain, and fever. Although most infections resolve without prolonged illness, complications can occasionally occur, including development of Guillain–Barré syndrome and reactive arthritis. [1] [2] Treatment is generally supportive, although antibiotics may be used in certain cases. The bacterium is distributed worldwide, and its prevalence and transmission vary across populations and geographic regions.

History

Campylobacter jejuni was originally described as Vibrio jejuni in 1931 due to its resemblance to other Vibrio species. In 1963, Seabald and Vérnon proposed the genus Campylobacter based on characteristics such as low levels of guanine and cytosine (G +C), non-fermentative metabolism, and microaerophilic growth requirements. [3] Vibrio jejuni was subsequently transferred to the genus Campylobacter in 1973.

The first well documented outbreak of human Campylobacter infection occurred in 1938, when contaminated milk associated with diarrhea among approximately 355 inmates at two state institutions in Illinois.. [3] Although bacteria resembling Campylobacter had been observed in humans as early as 1886, the organisms were first successfully isolated from human stool samples in 1972. Advances in laboratory cultivation techniques during the 1970s helped establish C. jejuni as an important cause of bacterial gastroenteritis. [4] In 1996, Campylobacter species accounted for 46% of laboratory-confirmed bacterial gastroenteritis cases reported through The CDC, USDA and FDA collaborating sites of the Foodborne Diseases Active Surveillance Network. [5]

The name Campylobacter means "curved rod", deriving from the Greek words kampylos (curved) and baktron (rod). Among the species within this genus, C. jejuni is considered important because of its role in human gastrointestinal infections and its worldwide public health significance. [6] [7]

Metabolism

C. jejuni has limited ability to metabolize sugars and primarily relies on amino acids as carbon and energy sources. [8] This is partly because it lacks key enzymes needed for conventional glycolysis, including glucokinase and 6-phosphofructokinase. [9] C. jejuni primarily metabolizes serine, aspartate, and glutamate, while some strains can also utilize asparagine and proline as additional carbon and energy sources. [3] If all of these are depleted, some strains can use proline as well. [3] These nutrients may be obtained from the host and metabolic activity of other gut microbes. [8]

C. jejuni uses several central metabolic pathways, including the citric acid cycle, a non-oxidative pentose phosphate pathway, gluconeogenesis, and fatty acid synthesis. [10] Serine is an important amino acid for growth and is transported into the cell by SdaC before being converted to pyruvate by the SdaA dehydratase. [9] Though this pyruvate cannot directly be converted into phosphoenolpyruvic acid (as C. jejuni lacks this synthetase), the pyruvate can enter the TCA cycle to form oxaloacetic acid intermediates that can be converted to phosphoenolpyruvic acid for gluconeogenesis. [10] This production of carbohydrates is important for the virulence factors of C. jejuni. [10] The pyruvate created from serine can also be converted to acetyl CoA and be applied to fatty acid synthesis or continue into the TCA cycle to create precursors for other biosynthetic pathways. [10] Aspartate and glutamate are both brought into the cell via Peb1A transport proteins. [9] Glutamate can be transaminated into aspartate, and aspartate can be deaminated to make fumerate that feeds into the TCA cycle as well. [9] Asparagine is also able to be deaminated into aspartate (which follows the process into the TCA cycle mentioned above). [9] While the amino acids listed above are able to be metabolized, C. jejuni is capable of taking in many of the other amino acids which helps to lower the anabolic cost of de novo synthesis. [10]

If other sources of carbon are exhausted, C. jejuni can also use acetate and lactate as carbon sources. [9] Acetate is a normal secreted byproduct of C. jejuni metabolism stemming from the recycling of CoA, and the absence of other carbon sources can cause C. jejuni to "switch" this reaction to take in acetate for the conversion to acetyl-CoA (catalyzed by phosphate acetyltransferase and acetate kinase enzymes). [9] [10] Lactate is a normal byproduct of many fermentative bacteria in the gut, and C. jejuni can take in and oxidize this lactate to supply pyruvate through the activity of dehydrogenase iron-sulfur enzyme complexes. [9]

The energetic needs of these anabolic pathways are met in multiple ways. The cytochrome c and quinol terminal oxidases allow for C. jejuni to use oxygen as a terminal electron acceptor for the reduced carriers produced through the TCA cycle (hence why C. jejuni is considered an obligate microaerophile). [11] The conversion of acetyl-CoA to acetate mentioned above has substrate-level phosphorylation take place, giving another form of energy production without the use of microaerophilic respiration. [10]

C. jejuni can use many different electron donors for its metabolic processes, using NADH and FADH most commonly – though C. jejuni uses NADH poorly compared to FADH due to a replacement of genes encoding subunits for NADH dehydrogenases for genes contributing to processes relating to FADH electron donation. [12] Aside from these donors, C. jejuni can turn to products from the host gut microbiota including hydrogen, lactate, succinate, and formate to contribute electrons; formate, for example, is generated through intestinal mixed-acid fermentation. [12] Unlike almost all other Campylobacter or Helicobacter species, C. jejuni can also accept electrons from sulfite and metabisulfite through its cytochrome c oxidoreductase system. [12]

While oxygen is mainly used as a terminal electron acceptor, C. jejuni can use nitrate, nitrite, sulfur oxides (such as dimethyl sulfoxide or trimethylamine N-oxide), or fumarate as terminal electron acceptors as well to survive as a microaerophilic bacterium. [12] Due to oxygen-limited conditions in the common areas of colonization, C. jejuni possesses two separate terminal oxidases with different affinities for oxygen, where the low affinity oxidase can directly retrieve electrons from menaquinones. [12] The adaptations allowing for multiple electron acceptors help to combat the problem with reactive oxygen species arising from the sole use of oxygen as well; C. jejuni cannot grow under strictly aerobic conditions. Enzymes C. jejuni carries to impede the effects of reactive oxygen species include: superoxide dismutase SodB, alkyl hydroxide reductase AhpC, catalase KatA, and thiol peroxidases Tpx and Bcp. [12]

Genome

The genome of C. jejuni strain NCTC11168 was published in 2000, revealing 1,641,481 base pairs (30.6% G+C) predicted to encode 1,654 proteins and 54 stable RNA species. The genome is unusual in that virtually no insertion sequences or phage-associated sequences and very few repeat sequences are found. One of the most striking findings in the genome was the presence of hypervariable sequences. These short homopolymeric runs of nucleotides were commonly found in genes encoding the biosynthesis or modification of surface structures, or in closely linked genes of unknown function. The apparently high rate of variation of these homopolymeric tracts may be important in the survival strategy of C. jejuni. [13] The genome was re-annotated in 2007 updating 18.2% of product functions. [14] Analysis also predicted the first pathogenicity island in C. jejuni among select strains, harbouring the bacteria's Type VI secretion system and putative cognate effectors. [15]

Initial transposon mutagenesis screens revealed 195 essential genes, although this number is likely to go up with additional analysis. [16]

Natural genetic transformation

C. jejuni is naturally competent for genetic transformation. [17] Natural genetic transformation is a sexual process involving DNA transfer from one bacterium to another through the intervening medium, and the integration of the donor sequence into the recipient genome by homologous recombination. C. jejuni freely takes up foreign DNA harboring genetic information responsible for antibiotic resistance. [17] Antibiotic resistance genes are more frequently transferred in biofilms than between planktonic cells (single cells that float in liquid media). [18]

Sources

Animal reservoirs such as wild poultry, domestic poultry, dogs, cats, and cattle are all sources of Campylobacter jejuni with poultry being the primary contributor to infection. Campylobacter jejuni can most commonly be found in the gastrointestinal tracts of both domestic and wild poultry species. In cattle, Campylobacter jejuni is normally a harmless commensal of the gastrointestinal tract and can cause campylobacteriosis in calves. It has also been isolated from wombat and kangaroo feces, being a cause of bushwalkers' diarrhea. Contaminated drinking water and unpasteurized milk provide an efficient means for distribution. Contaminated food is a major source of isolated infections, with incorrectly prepared meat and poultry as the primary source of the bacteria. [19] Moreover, surveys show that 20 to 100% of retail chickens are contaminated with many healthy chickens carrying Campylobacter jejuni in their intestinal tracts and often in high concentrations, up to 108 cfu/g. [20] The bacteria contaminate the carcasses due to poor hygiene during the slaughter process with contamination being primarily associated with reservoirs within the farm as well as crews contaminating equipment. Studies have investigated the chicken microbiome to understand how, why, and when campylobacter appears within the chicken gut. [21] The impact of industrial system production systems on the chicken gut microbiome and campylobacter prevalence has also been investigated. [22]

Raw milk is also a source of infections. The bacteria are often carried by healthy cattle and by flies on farms. Unchlorinated water may also be a source of infections. However, properly cooking chicken, pasteurizing milk, and chlorinating drinking water kill the bacteria. [23] While Salmonella is transmitted vertically in eggs, studies have shown Campylobacter jejuni is not. Therefore, consumption of eggs rarely results in human infection from campylobacter [24] although live C. jejuni on the eggshell has been detected on retail eggs [25] and can contaminate the interior if it comes in contact with it, for example through the fingers or while separating the yolk from the white.

Transmission

C. jejuni is a zoonotic disease meaning it is more commonly spread from animals to people than in between humans. People most often contract it by touching something that has been in contact with raw or undercooked chicken in addition to eating or touching poultry that is raw or undercooked. [26] Additionally, it can also be obtained from being in contact with animals or eating undercooked seafood. [26] The fecal oral route is the most common way it spreads as the bacterium is excreted in animal feces. [27] Infection can occur when an individual ingests food or water from a source that has been contaminated by Campylobacter jejuni. C. jejuni rarely causes disease in animals and infections are more common in lower income countries. [28] Deadly infections are not often seen in young adults but rather among the young and elderly. [28] Due to poor sanitation practices in some areas, the bacteria can also be found in ice and water. It is difficult to know the science behind its transmission due to its sporadic nature. [27] [28] The use of antibiotics and other treatments help in slowing and preventing the transmission of C. jejuni. [27] Another source of infection is contaminated water or unpasteurized milk. This is the case when people have been exposed to animal feces because poultry animals carry C. jejuni without showing symptoms. The bacteria then spreads to people via food preparation or animal contact. [29]

Virulence Factors

Flagella

Flagella are an important virulence factor of C. jejuni. Flagella enable motility, biofilm formation, host cell interactions and intestinal colonization in C. jejuni. They also aid in the secretion of proteins involved in infection. [8] Producing flagella requires high energy, so the bacterium must regulate their production. CsrA is a post-transcriptional regulatory protein that binds flaA mRNA to inhibit its translation into FlaA, the major filament of the structure. Studies of csrA mutant strains have identified changes in numerous proteins involved with motility, host-cell interactions, stress resistance, and metabolism. [30]

Chemotaxis

C. jejuni uses chemotaxis to adjust its movement in response to chemical gradients in its environment. [31] It can move toward chemical attractants and away from repellents, helping it respond to favorable and unfavorable conditions. [31]

Other virulence factors

The pgl locus enables C. jejuni to attach sugar groups and proteins through a process called N-linked glycosylation. This modification affects proteins involved in bacterial functions, including host adherence and invasion. [32] C. jejuni secretes Campylobacter invasive antigens (Cia), which facilitate invasion. The bacteria also produce cytolethal distending toxin s (CDT), which damage host-cell DNA and can disrupt the cell cycle, leading to cell enlargement, cell cycle arrest, and sometimes apoptosis. [33]

Pathogenesis

C. jejuni causes disease by moving through the intestinal environment, attaching to intestinal cells, sometimes entering those cells, producing toxins, and triggering inflammation and immune response.

Adherence and invasion

C. jejuni uses strategies to attach to and breach the intestinal epithelial layer of its host cells. [31] It uses proteases, particularly HtrA, to disrupt cell junctions and cross the epithelial barrier. [31] Host proteins such as fibronectin can serve as binding sites for C. jejuni and facilitate this process. [31] After entering a host cell, C. jejuni can survive inside membrane-bound compartments called Campylobacter-containing vacuoles. Host-cell transport mechanisms, including dynein, can help move these compartments toward the perinuclear region to avoid lysosomal degradation for up to 72 hours. [31]

Toxins and inflammatory mechanisms

C. jejuni causes intestinal disease through interactions with gut enterocytes, production of bacterial toxins, and the host's inflammatory response. [34] The best-characterized toxin produced by C. jejuni is cytolethal distending toxin (CDT). Although other toxin-like activities have been investigated, the contribution of individual secreted proteins to the development and severity of human disease is not fully understood.

The structure of C. jejuni's lipopolysaccharide (LPS), particularly its lipid A component, can influence how the immune system responds to the bacterium. Lipid A contains fatty acid chains that help determine how strongly the immune system is activated. One study found that LPS from a C. jejuni strain containing a mixture of tetra-acylated and hexa-acylated lipid A forms induced a moderate TLR4-mediated inflammatory response in mouse macrophages. Compared with E. coli LPS, it triggered lower levels of inflammatory cytokines. These findings suggest that differences in lipid A structure can influence the strength of immune response, although further research is needed to determine how these findings apply to humans. [35]

DNA repair

Bile in the intestines can function as a defensive barrier against colonization by C. jejuni. [36] [37] Exposure to the bile acid deoxycholate can induce oxidative stress and double-strand breaks in the DNA of C. jejuni. [38] [36] C. jejuni employs the AddAB DNA repair system to repair double-strand breaks through homologous recombination. [36] Mutants lacking the addAB genes exhibit increased sensitivity to deoxycholate and impaired DNA repair, whereas restoration of addAB function restores resistance to DNA damage from bile. [36] The AddAB system is also required for efficient colonization of the chicken intestine, indicating that DNA repair contributes to bacterial survival and persistence within the host. [36]

Immune response

Infection with C. jejuni stimulates intestinal cells and other components of the immune system to release chemokines, signaling proteins that help recruit immune cells to the site. Inflammatory chemokines such as CXCL1, CCL3/CCL4, CCL2, and CXCL10 are upregulated, further triggering the immune response. One pathway involves ADP-heptose, a bacterial molecule that activates ALPK1 and stimulates inflammatory signaling. [39] [31]

Neutrophil granulocytes use phagocytosis to combat C. jejuni infection, releasing antimicrobial proteins and proinflammatory substances. However, C. jejuni can influence the differentiation process of specific types of neutrophil granulocytes, triggering hypersegmentation and increased reactivity, which leads to delayed apoptosis and higher production of reactive oxygen species. [31]

After infection, B lymphocytes in the body increase the production of antibodies that specifically fight against C. jejuni flagellin. [31] Levels of all immunoglobulin classes rise during infection, with IgA playing a particularly important role because it binds and immobilizes organisms, causing them to aggregate and activate complement proteins that help eliminate the bacteria. [40]

The host immune responses and changes to intestinal environment contribute to the eventual control of the infection. However, the mechanisms responsible for the duration and resolution of infection are complex. [31]

Disease

Enteritis, a typical manifestation of a Campylobacter jejuni infection, results in inflammation as pictured above, in which eosinophil aggregation occurs. Eosinophilic enteritis, high mag.jpg
Enteritis, a typical manifestation of a Campylobacter jejuni infection, results in inflammation as pictured above, in which eosinophil aggregation occurs.

Campylobacteriosis is an infectious disease caused by bacteria of the genus Campylobacter. In most patients presenting with campylobacteriosis, symptoms develop within two to five days of exposure to the organism and illness typically lasts seven days following onset. [41] Infection with C. jejuni primarily causes enteritis, or inflammation of the intestine, with symptoms including abdominal pain, diarrhea (often bloody), fever, and malaise.

Some individuals experience a prodromal phase of symptoms for the first 1 to 3 days, in which the more severe portion of the disease occurs. The prodromal phase presents with symptoms including rigors, high fever, body aches, and dizziness. This is followed by the acute diarrheal phase, which usually lasts around 7 days. Abdominal pain can persist for weeks afterward. [42] The disease is usually self-limiting, meaning that symptoms resolve without prolonged illness. Possible complications of campylobacteriosis include Guillain–Barré syndrome and reactive arthritis. [42]

Complications

Although most Campylobacter infections are limited to the gastrointestinal tract, complications can occasionally occur. Local complications may include cholecystitis, pancreatitis, peritonitis, and gastrointestinal hemorrhage. Extraintestinal manifestations of campylobacter infection are rare and may include meningitis, endocarditis, septic arthritis, osteomyelitis, and neonatal sepsis. Bacteremia is detected in <1% of patients with campylobacter enteritis and is most likely to occur in patients who are immunocompromised or at the extremes of age. [43] Transient bacteremia in immunocompetent hosts with C. jejuni enteritis may be more common but not detected because the killing action rapidly clears most normal human serotypes, and blood cultures are not routinely performed for patients with acute gastrointestinal illness. [44]

Guillain–Barré syndome

Serious systemic illness caused by campylobacter infection rarely occurs but can lead to sepsis and death. Guillain–Barré syndrome is an uncommon but serious complication of C. jejuni infection which can induce muscle weakness and neuromuscular paralysis. Over time, the paralysis is typically reversible to some extent; nonetheless, about 3-10% of patients with GBS die. [45] GBS can develop after C. jejuni infection because some antibodies produced against the bacterium mistakenly recognize similar molecules on peripheral nerves. This process, known as molecular mimicry, can lead to immune mediated nerve damage. [45]

Reactive arthritis

Reactive arthritis is a post-infectious inflammatory joint disorder that can develop after Campylobacter infection. It typically affects a small proportion of infected individuals due to its association with a particular genetic make-up. Presence of the human leukocyte antigen B27 (HLA-B27) is associated with increased susceptibility. Symptoms usually develop within several weeks of infection and may persist after gastrointestinal symptoms have resolved. [46]

Diagnosis

Diagnostic tests are available to identify campylobacter infections, including those caused by C. jejuni. [42] The stool culture is considered the gold standard for diagnosing C. jejuni, [47] and selective culture techniques are used to distinguish it from other variants. [42] Stool cultures are grown on specially selective "CAMP" agar plates at 42 °C, the normal avian body temperature, in an atmosphere of 85% N2, 10% CO2, and 5% O2. C. jejuni requires these conditions due to being thermophilic and microaerophilic. [48] A selective blood agar medium (Skirrow's medium) can be used. Greater selectivity can be gained with an infusion of a cocktail of antibiotics: vancomycin, polymixin-B, trimethoprim, and actidione (Preston's agar). [49] A final diagnosis from a stool sample requires a gram stain or phase contrast microscopy. [50]

Aside from stool cultures, C. jejuni can be detected using enzyme immunoassay (EIA) or polymerase chain reaction (PCR). [42] These methods are more sensitive than stool cultures, but PCR tends to be the most sensitive, especially in children and developing countries. [51]

CharacteristicResult
Growth at 25 °C−
Growth at 35–37 °C+
Growth at 42 °C+
Nitrate reduction+
Catalase test +
Oxidase test +
Growth on MacConkey agar +
Motility (wet mount)+
Glucose use−
Hippurate hydrolysis+
Resistance to nalidixic acid −
Resistance to cephalothin +
Scanning electron micrograph depicting a number of Campylobacter jejuni bacteria Campylobacter jejuni 5778 lores.jpg
Scanning electron micrograph depicting a number of Campylobacter jejuni bacteria

Suspicious colonies can be identified when oxidase and catalase activity occur. C. jejuni can be readily identified by commercial phenotypic assays. Alternatively, molecular assays based on PCR amplification of the 16S rRNA are also available. [52]

Treatment

Campylobacter infections tend to be mild, requiring only hydration and electrolyte repletion while diarrhea lasts. Maintenance of electrolyte balance, not antibiotic treatment, is the cornerstone of treatment for campylobacter enteritis. Depending on the degree of dehydration, alternate measures may be taken including parenteral methods of hydration. [53] [54]

Antibiotic treatment

Antibiotic treatment for Campylobacter infections are usually not recommended. Antibiotics are required for treating high-risk patients, including immunocompromised and older individuals. Severe cases exhibiting symptoms such as bloody stools, fever, severe abdominal pain, pregnancy, infection with HIV, and prolonged illness (symptoms that last > 1 week) may also require treatment by antibiotics to help to shorten the duration of the symptoms. [42] [45] [55] Researchers advise to treat these infections with macrolide antibiotics, such as erythromycin or azithromycin. Erythromycin is inexpensive and limits toxic exposure to patients; however, resistance rates are reportedly increasing. Nonetheless, erythromycin use is continued, and resistance rates remain below 6%. [56] Azithromycin usage is increasing due to various drug characteristics, including its once-a-day dosage, tolerability by patients, decreased relation to Infantile hypertrophic pyloric stenosis (IHPS), and less negative side effects compared to erythromycin. Fluoroquinolones are an alternative treatment, however resistance rates are increasing. [57]

Antibiotic resistance

Fluoroquinolones were first approved as a treatment for campylobacter infections in 1986, and were later U.S. Food and Drug Administration (FDA) approved in 1996, so as to control infections in poultry flocks. [56] The CDC began monitoring campylobacter in 1997 in the National Antimicrobial Resistance Monitoring System (NARMS). On September 12, 2005, the FDA suspended the use of all fluoroquinolones in poultry production, and the prevalence of campylobacter strains that are fluoroquinolone resistant in poultry flocks, poultry products, production facilities, and human infections became vital to monitor; this was in an effort to determine if the fluoroquinolone ban led to a reduction in the antibiotic-resistant strains. [58] Despite this, data from NARMS indicated ciprofloxacin, a fluoroquinolone, had microbial resistance rates of 17% in 1997–1999, which further increased to 27% in 2015–2017, and now may be as high as 34%. [56] A presence of drug-resistance to ciprofloxacin has been observed in isolate studies, as well as significant drug-resistance among campylobacter to the antibiotics nalidixic acid and tetracyclines. There is a low rate of resistance to erythromycin, the preferred source of antibiotic treatment for campylobacter infections, however resistant strains have been detected in many countries among sources of the origin of food from farm animals. [59]

Prevention

Some simple food-handling practices can help prevent campylobacter infections. [41]

Epidemiology

Frequency

United States

An estimated 1.9 million cases of campylobacter enteritis occur annually. Campylobacter enteritis is responsible for approximately 8% of gastroenteritis cases, with C. jejuni being the most common contributor. [60] [61] Campylobacter has a large animal reservoir, with up to 100% of poultry, including chickens, turkeys, and waterfowl, having asymptomatic intestinal infections. The major reservoirs of C. fetus are cattle and sheep. More than 90% of campylobacter infections occur during the summer months due to undercooked meats from outdoor cooking. [42] Nonetheless, the incidence of campylobacter infections has been declining. Changes in the incidence of culture-confirmed Campylobacter infections have been monitored by the Foodborne Diseases Active Surveillance Network (FoodNet) since 1996. In 2020, campylobacter incidence showed a 30% decrease compared with 2018, with the incidence sitting at 14 cases per 100,000 individuals. [62]

Europe

In 2020, there were around 120,000 cases of C. jejuni infection, which showed a decline of about 25.4% compared to the previous year. [31] However, the COVID-19 pandemic may have influenced this decrease, and its statistical significance is yet to be determined. [31] C. jejuni infections tend to peak in July, which could be linked to the rise in temperature worldwide. [31] This pattern is associated with an increased reflection rate of the bacteria, which needs further investigation to establish any potential correlations. [31]

Globally

Campylbacter jejuni infections are extremely common worldwide, but global infection rates have not been recorded. The Czech Republic reported the highest national rate, which peaked in 2019 at 215 per 100,000 population. [63] C. jejuni infection is a significant global health issue, with infection rates ranging from 0.3 to 2.9%. [31] It is a widespread infection that affects individuals of all ages but is more prevalent in developing countries. [31] In these areas, diarrhea is the most common clinical presentation, and it has a severe impact on children. [31]

Sex

Men are more frequently infected with Campylobacter than Women. [64] Homosexual men my be particularly susceptible to campylobacter-related species like Helicobacter cinaedi and Helicobacter fennelliae . [65]

Age

Campylobacter infections can occur in all age groups. Studies show a peak incidence in children younger than 1 year and in people aged 15–29 years. The age-specific attack rate is highest in young children. In the United States, the highest incidence of Campylobacter infection in 2010 was in children younger than 5 years and was 24.4 cases per 100,000 population. [55] Community based studies done in developing countries show about 60,000 out of every 100,000 children under five years old are affected by campylobacter infections. [42]

References

  1. ↑ Fujimoto S, Amako K (June 1990). "Guillain-Barré syndrome and Campylobacter jejuni infection". Lancet. 335 (8701): 1350. doi:10.1016/0140-6736(90)91234-2. PMID   1971411. S2CID   38312888.
  2. ↑ "What is Reactive Arthritis?". Reactive Arthritis. 6 February 2019.
  3. 1 2 3 4 Epps SV, Harvey RB, Hume ME, et al. (November 2013). "Foodborne Campylobacter: infections, metabolism, pathogenesis and reservoirs". International Journal of Environmental Research and Public Health. 10 (12): 6292–6304. Bibcode:2013IJERP..10.6292E. doi: 10.3390/ijerph10126292 . PMC   3881114 . PMID   24287853.
  4. ↑ Allos BM (April 2001). "Campylobacter jejuni Infections: update on emerging issues and trends". Clinical Infectious Diseases. 32 (8): 1201–1206. doi:10.1086/319760. PMID   11283810.
  5. ↑ "Emerging Infectious Diseases journal". wwwnc.cdc.gov. Retrieved 11 October 2026.
  6. ↑ Ammar AM, El-Naenaeey ES, El-Hamid MI, et al. (1 February 2021). "Campylobacter as a Major Foodborne Pathogen: A Review of ITS Characteristics, Pathogenesis, Antimicrobial Resistance and Control". Journal of Microbiology, Biotechnology and Food Sciences. 10 (4): 609–619. doi: 10.15414/jmbfs.2021.10.4.609-619 . ISSN   1338-5178.
  7. ↑ Gundogdu O, Wren BW (March 2020). "Microbe Profile: Campylobacter jejuni – survival instincts". Microbiology. 166 (3): 230–232. doi: 10.1099/mic.0.000906 . PMID   32228803. S2CID   214750673.
  8. 1 2 3 Tegtmeyer N, Sharafutdinov I, Harrer A, et al. (2021). "Campylobacter Virulence Factors and Molecular Host-Pathogen Interactions". In Backert S (ed.). Current Topics in Microbiology and Immunology. Vol. 431. Cham: Springer International Publishing. pp. 169–202. doi:10.1007/978-3-030-65481-8_7. ISBN   978-3-030-65480-1. PMID   33620652.
  9. 1 2 3 4 5 6 7 8 Stahl M, Butcher J, Stintzi A (2012). "Nutrient acquisition and metabolism by Campylobacter jejuni". Frontiers in Cellular and Infection Microbiology. 2: 5. doi: 10.3389/fcimb.2012.00005 . PMC   3417520 . PMID   22919597.
  10. 1 2 3 4 5 6 7 Gao B, Vorwerk H, Huber C, et al. (May 2017). Waldor M (ed.). "Metabolic and fitness determinants for in vitro growth and intestinal colonization of the bacterial pathogen Campylobacter jejuni". PLOS Biology. 15 (5) e2001390. doi: 10.1371/journal.pbio.2001390 . PMC   5438104 . PMID   28542173.
  11. ↑ Sellars MJ, Hall SJ, Kelly DJ (August 2002). "Growth of Campylobacter jejuni supported by respiration of fumarate, nitrate, nitrite, trimethylamine-N-oxide, or dimethyl sulfoxide requires oxygen". Journal of Bacteriology. 184 (15): 4187–4196. Bibcode:2002JBact.184.4187S. doi:10.1128/JB.184.15.4187-4196.2002. PMC   135223 . PMID   12107136.
  12. 1 2 3 4 5 6 Hofreuter D (2014). "Defining the metabolic requirements for the growth and colonization capacity of Campylobacter jejuni". Frontiers in Cellular and Infection Microbiology. 4: 137. doi: 10.3389/fcimb.2014.00137 . PMC   4178425 . PMID   25325018.
  13. ↑ Parkhill J, Wren BW, Mungall K, et al. (February 2000). "The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences". Nature. 403 (6770): 665–668. Bibcode:2000Natur.403..665P. doi: 10.1038/35001088 . PMID   10688204.
  14. ↑ Gundogdu O, Bentley SD, Holden MT, et al. (June 2007). "Re-annotation and re-analysis of the Campylobacter jejuni NCTC11168 genome sequence". BMC Genomics. 8 (1) 162. Bibcode:2007BMCG....8..162G. doi: 10.1186/1471-2164-8-162 . PMC   1899501 . PMID   17565669.
  15. ↑ Robinson L, Liaw J, Omole Z, et al. (29 June 2021). "Bioinformatic Analysis of the Campylobacter jejuni Type VI Secretion System and Effector Prediction". Frontiers in Microbiology. 12 694824. doi: 10.3389/fmicb.2021.694824 . PMC   8285248 . PMID   34276628.
  16. ↑ Stahl M, Stintzi A (June 2011). "Identification of essential genes in C. jejuni genome highlights hyper-variable plasticity regions". Functional & Integrative Genomics. 11 (2): 241–257. doi:10.1007/s10142-011-0214-7. PMID   21344305. S2CID   24054117.
  17. 1 2 Bae J, Oh E, Jeon B (December 2014). "Enhanced transmission of antibiotic resistance in Campylobacter jejuni biofilms by natural transformation". Antimicrobial Agents and Chemotherapy. 58 (12): 7573–7575. doi:10.1128/AAC.04066-14. PMC   4249540 . PMID   25267685.
  18. ↑ Michaelis C, Grohmann E (February 2023). "Horizontal Gene Transfer of Antibiotic Resistance Genes in Biofilms". Antibiotics. 12 (2): 328. doi: 10.3390/antibiotics12020328 . PMC   9952180 . PMID   36830238.
  19. ↑ Colles FM, McCarthy ND, Howe JC, et al. (January 2009). "Dynamics of Campylobacter colonization of a natural host, Sturnus vulgaris (European starling)". Environmental Microbiology. 11 (1): 258–267. Bibcode:2009EnvMi..11..258C. doi:10.1111/j.1462-2920.2008.01773.x. PMC   2702492 . PMID   18826435.
  20. ↑ Rosenquist H, Sommer HM, Nielsen NL, et al. (April 2006). "The effect of slaughter operations on the contamination of chicken carcasses with thermotolerant Campylobacter". International Journal of Food Microbiology. 108 (2): 226–232. doi:10.1016/j.ijfoodmicro.2005.12.007. PMID   16478636.
  21. ↑ Ijaz UZ, Sivaloganathan L, McKenna A, et al. (October 2018). "Comprehensive Longitudinal Microbiome Analysis of the Chicken Cecum Reveals a Shift From Competitive to Environmental Drivers and a Window of Opportunity for Campylobacter". Frontiers in Microbiology. 9 2452. doi: 10.3389/fmicb.2018.02452 . PMC   6196313 . PMID   30374341.
  22. ↑ McKenna A, Ijaz UZ, Kelly C, et al. (September 2020). "Impact of industrial production system parameters on chicken microbiomes: mechanisms to improve performance and reduce Campylobacter". Microbiome. 8 (1) 128. doi: 10.1186/s40168-020-00908-8 . PMC   7488076 . PMID   32907634.
  23. ↑ Center for Food Safety and Applied Nutrition. "Bad Bug Book – BBB – Campylobacter jejuni". www.fda.gov. Archived from the original on 18 June 2013. Retrieved 18 April 2016.
  24. ↑ Fonseca BB, Beletti ME, de Melo RT, et al. (2014). "Campylobacter jejuni in commercial eggs". Brazilian Journal of Microbiology. 45 (1): 76–79. doi:10.1590/S1517-83822014000100011. PMC   4059329 . PMID   24948916.
  25. ↑ Dorn-In S, Daldrup E, Mang S, et al. (2024). "Viable Campylobacter jejuni on eggshells and its potential to cross-contaminate egg white and yolk when using a manual separation technique, determined by culture and propidium monoazide (PMA) qPCR". Journal of Food Protection. 87 (4) 100246. doi: 10.1016/j.jfp.2024.100246 . ISSN   0362-028X. PMID   38369191.
  26. 1 2 "Questions and Answers | Campylobacter | CDC". www.cdc.gov. 16 February 2023. Retrieved 28 February 2024.
  27. 1 2 3 Facciolà A, Riso R, Avventuroso E, et al. (June 2017). "Campylobacter: from microbiology to prevention". Journal of Preventive Medicine and Hygiene. 58 (2): E79–E92. PMC   5584092 . PMID   28900347.
  28. 1 2 3 "Campylobacter". www.who.int. Retrieved 28 February 2024.
  29. ↑ Hudson JA, Nicol C, Wright J, et al. (July 1999). "Seasonal variation of Campylobacter types from human cases, veterinary cases, raw chicken, milk and water". Journal of Applied Microbiology. 87 (1): 115–24. Bibcode:1999JApMb..87..115H. doi:10.1046/j.1365-2672.1999.00806.x. PMID   10432592.
  30. ↑ El Abbar FM, Li J, Owen HC, et al. (7 August 2019). "RNA Binding by the Campylobacter jejuni Post-transcriptional Regulator CsrA". Frontiers in Microbiology. 10 1776. doi: 10.3389/fmicb.2019.01776 . PMC   6692469 . PMID   31447808.
  31. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Kemper L, Hensel A (May 2023). "Campylobacter jejuni: targeting host cells, adhesion, invasion, and survival". Applied Microbiology and Biotechnology. 107 (9): 2725–2754. doi:10.1007/s00253-023-12456-w. PMC   10027602 . PMID   36941439.
  32. ↑ Cain JA, Dale AL, Sumer-Bayraktar Z, et al. (1 August 2020). "Identifying the targets and functions of N-linked protein glycosylation in Campylobacter jejuni". Molecular Omics. 16 (4): 287–304. doi:10.1039/D0MO00032A. ISSN   2515-4184. PMID   32347268.
  33. ↑ Kemper L, Hensel A (May 2023). "Campylobacter jejuni: targeting host cells, adhesion, invasion, and survival". Applied Microbiology and Biotechnology. 107 (9): 2725–2754. doi:10.1007/s00253-023-12456-w. ISSN   0175-7598. PMC   10027602 . PMID   36941439.
  34. ↑ Kaakoush NO, Castaño-Rodríguez N, Mitchell HM, et al. (July 2015). "Global Epidemiology of Campylobacter Infection". Clinical Microbiology Reviews. 28 (3): 687–720. doi:10.1128/CMR.00006-15. PMC   4462680 . PMID   26062576.
  35. ↑ Korneev KV, Kondakova AN, Sviriaeva EN, et al. (2018). "Hypoacylated LPS from Foodborne Pathogen Campylobacter jejuni Induces Moderate TLR4-Mediated Inflammatory Response in Murine Macrophages". Frontiers in Cellular and Infection Microbiology. 8 58. doi: 10.3389/fcimb.2018.00058 . PMC   5835049 . PMID   29535976.
  36. 1 2 3 4 5 Gourley CR, Negretti NM, Konkel ME (October 2017). "The food-borne pathogen Campylobacter jejuni depends on the AddAB DNA repair system to defend against bile in the intestinal environment". Scientific Reports. 7 (1) 14777. Bibcode:2017NatSR...714777G. doi: 10.1038/s41598-017-14646-9 . PMC   5665897 . PMID   29089630.
  37. ↑ Alrubaye B, Abraha M, Almansour A, et al. (2019). "Microbial metabolite deoxycholic acid shapes microbiota against Campylobacter jejuni chicken colonization". PLOS ONE. 14 (7) e0214705. Bibcode:2019PLoSO..1414705A. doi: 10.1371/journal.pone.0214705 . PMC   6611565 . PMID   31276498.
  38. ↑ Negretti NM, Gourley CR, Clair G, et al. (November 2017). "The food-borne pathogen Campylobacter jejuni responds to the bile salt deoxycholate with countermeasures to reactive oxygen species". Scientific Reports. 7 (1) 15455. Bibcode:2017NatSR...715455N. doi: 10.1038/s41598-017-15379-5 . PMC   5684402 . PMID   29133896.
  39. ↑ Sidor K, Skirecki T (May 2023). "A Bittersweet Kiss of Gram-Negative Bacteria: The Role of ADP-Heptose in the Pathogenesis of Infection". Microorganisms. 11 (5): 1316. doi: 10.3390/microorganisms11051316 . PMC   10221265 . PMID   37317291.
  40. ↑ Gilroy R, Wedley A, Jopson S, et al. (23 August 2024), The immunobiology of persistent intestinal infection by Campylobacter jejuni in the chicken, doi:10.1101/2024.08.23.609314 , retrieved 6 October 2026
  41. 1 2 "Campylobacter: Questions and Answers". U.S. Centers for Disease Control and Prevention. 20 December 2019. Retrieved 2 January 2020.
  42. 1 2 3 4 5 6 7 8 Fischer GH, Hashmi MF, Paterek E (2024). "Campylobacter Infection". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID   30725718 . Retrieved 29 February 2024.
  43. ↑ Zerbato V, Guicciardi S, Baldan R, et al. (29 June 2026). "Clinical Outcomes of Campylobacter Bacteremia: A Systematic Review with Meta-Analysis". Pathogens. 15 (7). Basel, Switzerland: 686. doi: 10.3390/pathogens15070686 . ISSN   2076-0817. PMC   13414677 . PMID   42515013.
  44. ↑ Patel V, Waheed H, Khan RS, et al. (10 April 2026). "Campylobacter jejuni Bacteremia in an Immunocompromised Host: A Rare Case Report". Cureus. 18 (4) e106793. doi: 10.7759/cureus.106793 . ISSN   2168-8184. PMC   13157825 . PMID   42116986.
  45. 1 2 3 Finsterer J (17 November 2022). "Triggers of Guillain–Barré Syndrome: Campylobacter jejuni Predominates". International Journal of Molecular Sciences. 23 (22) 14222. doi: 10.3390/ijms232214222 . ISSN   1422-0067. PMC   9696744 . PMID   36430700.
  46. ↑ Pogreba-Brown K, Austhof E, Tang X, et al. (1 September 2021). "Enteric Pathogens and Reactive Arthritis: Systematic Review and Meta-Analyses of Pathogen-Associated Reactive Arthritis" . Foodborne Pathogens and Disease. 18 (9). SAGE Publications: 627–639. doi:10.1089/fpd.2020.2910. ISSN   1535-3141. PMID   34255548.
  47. ↑ Platts-Mills JA, Liu J, Gratz J, et al. (2014). "Detection of Campylobacter in stool and determination of significance by culture, enzyme immunoassay, and PCR in developing countries". Journal of Clinical Microbiology. 52 (4): 1074–1080. doi:10.1128/JCM.02935-13. ISSN   1098-660X. PMC   3993515 . PMID   24452175.
  48. ↑ Davis L, DiRita V (August 2008). "Growth and Laboratory Maintenance of Campylobacter jejuni". Current Protocols in Microbiology. Vol. 10. pp. Unit 8A.1.1-8A.1.7. doi:10.1002/9780471729259.mc08a01s10. hdl: 2027.42/154622 . PMID   18729058.
  49. ↑ Bolton FJ, Robertson L (April 1982). "A selective medium for isolating Campylobacter jejuni/coli". Journal of Clinical Pathology. 35 (4): 462–467. doi:10.1136/jcp.35.4.462. PMC   497682 . PMID   7042765.
  50. ↑ "Diagnosis of a Campylobacter Infection". Marler Clark. Retrieved 9 April 2024.
  51. ↑ Platts-Mills JA, Liu J, Gratz J, et al. (April 2014). Diekema DJ (ed.). "Detection of Campylobacter in stool and determination of significance by culture, enzyme immunoassay, and PCR in developing countries". Journal of Clinical Microbiology. 52 (4): 1074–1080. doi:10.1128/JCM.02935-13. PMC   3993515 . PMID   24452175.
  52. ↑ Tille PM (2014). Bailey & Scott's diagnostic microbiology (13th ed.). St. Louis, Missouri: Elsevier. p. 419. ISBN   978-0-323-08330-0.
  53. ↑ Fischer GH, Hashmi MF, Paterek E (2024). "Campylobacter Infection". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID   30725718 . Retrieved 29 February 2024.
  54. ↑ "Antibiotic Resistance | Campylobacter". U.S. Centers for Disease Control and Prevention (CDC). 27 June 2022. Retrieved 11 April 2024.
  55. 1 2 "Campylobacter". Foodsafety.gov. Retrieved 18 April 2016.
  56. 1 2 3 Yan R, M'ikanatha NM, Nachamkin I, et al. (December 2023). "Prevalence of ciprofloxacin resistance and associated genetic determinants differed among Campylobacter isolated from human and poultry meat sources in Pennsylvania". Food Microbiology. 116 104349. doi:10.1016/j.fm.2023.104349. ISSN   0740-0020. PMID   37689423.
  57. ↑ Eiland LS, Jenkins LS (1 January 2008). "Optimal Treatment of Campylobacter Dysentery". The Journal of Pediatric Pharmacology and Therapeutics. 13 (3): 170–174. doi:10.5863/1551-6776-13.3.170. ISSN   1551-6776. PMC   3462042 . PMID   23055879.
  58. ↑ Price LB, Lackey LG, Vailes R, et al. (July 2007). "The persistence of fluoroquinolone-resistant Campylobacter in poultry production". Environmental Health Perspectives. 115 (7): 1035–1039. Bibcode:2007EnvHP.115.1035P. doi:10.1289/ehp.10050. PMC   1913601 . PMID   17637919.
  59. ↑ Portes AB, Panzenhagen P, Pereira Dos Santos AM, et al. (March 2023). "Antibiotic Resistance in Campylobacter: A Systematic Review of South American Isolates". Antibiotics. 12 (3): 548. doi: 10.3390/antibiotics12030548 . PMC   10044704 . PMID   36978415.
  60. ↑ CDC (28 September 2026). "About Campylobacter infection". Campylobacter Infection (Campylobacteriosis). Retrieved 7 October 2026.
  61. ↑ Derakhshan-sefidi M, Bakhshi B, Hamidi F, et al. (24 December 2025). "Prevalence and antimicrobial resistance patterns of Campylobacter spp. Causing human gastroenteritis in Iran (2000–2025): a systematic review and meta-analysis". BMC Infectious Diseases. 25 (1): 1742. doi: 10.1186/s12879-025-12057-0 . ISSN   1471-2334. PMC   12729080 . PMID   41444938.
  62. ↑ CDC (14 October 2018). "Template Package 4". Centers for Disease Control and Prevention. Retrieved 7 October 2026.
  63. ↑ Liu F, Lee SA, Xue J, et al. (28 November 2022). "Global epidemiology of campylobacteriosis and the impact of COVID-19". Frontiers in Cellular and Infection Microbiology. 12. Frontiers. doi: 10.3389/fcimb.2022.979055 . ISSN   2235-2988. PMC   9742372 . PMID   36519137.
  64. ↑ Green MS, Schwartz N, Peer V (25 August 2020). "Sex differences in campylobacteriosis incidence rates at different ages - a seven country, multi-year, meta-analysis. A potential mechanism for the infection". BMC Infectious Diseases. 20 (1): 625. doi: 10.1186/s12879-020-05351-6 . ISSN   1471-2334. PMC   7445732 .
  65. ↑ "Emerging Infectious Diseases journal". wwwnc.cdc.gov. doi:10.3201/eid2704.202337 . Retrieved 7 October 2026.